Related Experiment Videos
[Pilot study-previously treated advanced non-small cell lung cancer].
Shigetoshi Shirahama1, Takamichi Aritomi, Sadanori Takeo
1First Dept. of Internal Medicine, School of Medicine, Fukuoka University.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 5, 2005
Summary
Weekly paclitaxel infusions show good efficacy and low toxicity in advanced non-small cell lung cancer (NSCLC) patients. This pilot study suggests a promising treatment option for NSCLC management.
Area of Science:
- Oncology
- Pharmacology
Context:
- Advanced non-small cell lung cancer (NSCLC) presents significant treatment challenges.
- Previous treatment regimens for NSCLC often involve complex administration schedules and varying toxicity profiles.
Purpose:
- To evaluate the safety and efficacy of a weekly 1-hour paclitaxel infusion regimen.
- To assess the clinical outcomes and toxicity associated with this paclitaxel administration schedule in NSCLC patients.
Summary:
- A pilot study treated 10 previously-treated advanced NSCLC patients with weekly paclitaxel (80 mg/m2) via 1-hour infusion.
- Six patients achieved partial response, with a median time to progression of 5 months.
- The regimen demonstrated low toxicity, with uncommon severe non-hematological side effects like grade 1 neuropathy.
Impact:
- This weekly paclitaxel regimen shows favorable clinical efficacy with manageable toxicity in advanced NSCLC.
- The findings support the potential of this outpatient-friendly regimen for NSCLC treatment.